• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comment Learning from TARDIS: time for more focused trials in stroke prevention
Antithrombotic therapy immediately following stroke is important to minimise the risk of recurrence, but the optimum choice and number of drugs to use are unclear, and efficacy in preventing thrombosis needs to be weighed against bleeding risk. In The Lancet, the TARDIS investigators report findings from a randomised trial1 that tested intensive antiplatelet therapy with three agents (aspirin, clopidogrel, and dipyridamole) against therapy based on current UK guidelines2 (either clopidogrel, or aspirin plus dipyridamole) for 30 days in patients with transient ischaemic attack (TIA) or ischaemic stroke.
Source: LANCET - December 20, 2017 Category: General Medicine Authors: Pierre Amarenco Tags: Comment Source Type: research

Every Little Anniversary
One of the things they tell you after they’ve informed you that you have cancer or that you’ve had a stroke—after they tell you about the resections and the radiation—after they tell you about the aspirin and the clopidogrel—after you’re stable medically but still more than a little unstable emotionally—is to look for a support group. I had the kind of cancer that you learn about in medical school and then never see. I was decades younger than most of my physicians’ patients with stroke. The local support groups didn’t seem to fit me. I looked online at first, but then—even though I found a few people w...
Source: JAMA - December 1, 2015 Category: Journals (General) Source Type: research